Hello misui143, I have enjoyed reading your intelligent

New Post Public Reply Private Reply Replies (1) Message Board
blafarm misiu143 #20056
545
Hello misui143,

I have enjoyed reading your intelligent and informed posts since arriving here.

Quote:
It is very nice that you are a new poster , you are here since February 7, 2020


Yes, that is true. I recently joined after spending too much time reading caustic and baseless posts on Seeking Alpha. However, that was not my first post. If you are so inclined you can inspect my other posts using this link: https://investorshangout.com/profile/latestposts/id/62885. Feel free to also inspect my very few posts on "CYDY IH Eyes Only" board.

Quote:
But look to me that you all the way surprised !!!!!.
You surprise with any good information given by the company....not important what Dr NP or Dr Patterson said .......


Not exactly sure what you mean or what you are implying. I am thrilled with reports of what this little molecule can do. The potential indications seem to keep growing, and I find myself thinking about all of the people who can maybe be helped or saved by this drug.

I find Dr. Patterson to be extremely informed, articulate and credible. Frankly, I wish that he was the Chief Medical Officer or Chief Scientific Officer of the company, and that he participated in ALL conference calls, and ALL videos. Dr. NP has clearly accomplished what few others in the industry could ever do, through sheer will and perseverance.

Quote:
" To this day , I am particularly confused as to why BP has no interest in the company "......( how you know that ?? ))


I don't know that, this is simply what it looks like from my outside perspective. I see no investments by, no co-development with, and no licensing deals with BP. I only see a deal with V that, lets face it, is not exactly the entity one would select as a business partner, if one had other options.

Not surprisingly, this leads to confusion. Why would such an important drug not be capturing the attention of BP? More specifically, what pharmaceutical company would not want to participate, on any level, with CYDY's impressive pipeline of indications? Maybe you know more details regarding historical interest expressed by BP -- if so, please share your knowledge.

Quote:
"Discounting COVID-19 as it is completely unproven " ....( really ??, well this is not what Dr Paterson is saying )


I must admit being surprised by this remark. If I am not mistaken, I believe you might be a doctor and/or a person of science. Forgive me if I am mistaken, however, when exactly did you decide that a hypothesis was a "proven" fact -- just because someone else said it was?

In my world, hypotheses are not considered proven facts -- until they are empirically tested and confirmed to be facts. I would be absolutely thrilled if leronlimab had efficacy in treating those unfortunate souls stricken by COVID-19. There are people dying all over the world. Can you imagine if leronlimab saved those lives?

However, until such time that leronlimab is actually tested and proven to save the lives of those stricken by COVID-19 -- it remains theoretical. Yes, one can say (as Dr. Paterson has) that the MOA has a good chance of being efficacious -- but that's why every pharmaceutical company in the world conducts clinical trials. Otherwise, everyone would be taking drugs simply because someone else said it would work. Frankly, I don't know a doctor or scientist who would disagree with this logic.

Quote:
"Whatever it is , there is something wrong with this picture " ( how do you know that ?? ))


I believe that I have generally expressed this notion above. However, I guess my issue is that I don't quite understand how a molecule that has all appearances of being, literally, one of the most important drugs in the history of mankind, is not widely known, and not being aggressively courted by BP.

Let's do a quick review of potential indications:

Esophagus, Squamous Head & Neck, Melanoma, Brain-Glioblastoma, Throat, Lung including Non-Small Cell, Stomach, Colon Carcinoma, Breast, Testicular, Ovarian, Uterine, Pancreas, Bladder, Thyroid, other Endocrine, Blood/Bone Marrow CLL, AML, Hodgkin’s and non-Hodgkin’s lymphoma, other liquid/Blood Tumors, Sarcomas, Crohn’s Disease, IBS (Inflammatory Bowel Syndrome), MS (Multiple Sclerosis) , Hashimoto’s Thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Graves’ Disease, Sjogren’s Syndrome, Myasthenia gravis

Have I left anything out?

So, I'm sure you can imagine how a relatively new investor, who sees this extraordinary and mind-boggling list of potential indications, and doesn't see any tangible evidence of BP interest -- might say: "there is something wrong with this picture".

Quote:
And then you say... " I am long " ...really ... why ..??


Simply put -- I want to believe. I want to believe that a single drug can miraculously address this amazing plurality of diseases. I want to believe that millions of people suffering from these diseases can maybe have the opportunity to live long, healthy, and productive lives. I want to believe that the families and friends of those inflicted will have their loved ones in their lives for many years to come. And, in the interest of full disclosure, I sure wouldn't mind a financial benefit from my support of the company relating to my investment.

I believe I have adequately addressed your questions. It does make me sad to recognize that your curious line of inquiry has the trappings of someone who thinks that I am here specifically to spread negative information for financial gain. Allow me to disabuse you of that notion. I do not short this stock. I am long and strong, that is, until such time that the investment thesis is disproved. There's nothing more I can write that will dissuade you from that incorrect characterization.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI and Workforce Transformation: Zellis Connect 2026

Updated Category News Views 2

AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 4

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Early Orders Key for Custom Kids' Gifts This Season

Updated Category News Views 0

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Continue Reading
Nuix Leverages AI for Transformative Legal Review

Updated Category News Views 1

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 3

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 7

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
PBC 2026 Forum: Philanthropic Titans Collide in HK

Updated Category News Views 0

A Decade of Philanthropic Discourse The winds of change blew through Hong Kong’s West Kowloon Cultural District today, marking the tenth anniversary of the PBC 2026 forum—an event that’s got everyone from government bigwigs to sports icons chatting. Convened by The Hong Kong Jockey Club Charities Trust alongside the Institute of Philanthropy, this two-day journey is...

Continue Reading
SKF's Automotive Arm Set for Stockholm Debut in Dec

Updated Category News Views 0

The Big Spin-Off Play: SKF Vertevo So, SKF is at it again, pushing their Automotive business out the door as a newly minted public company—SKF Vertevo—on the horizon. It's like watching a mother bird kick the fledgling out of the nest. The Board's cooked up this spin-off strategy, and they're eyeing the Nasdaq Stockholm as the breeding ground, with the gears all set...

Continue Reading
La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 2

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 0

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading

Top 5 Most Recently Viewed Articles

HFCL's Eka™ Fiber Revolutionizes Telecom Connectivity in Europe

Updated Category News Views 150

HFCL Launches Eka™ Fiber at the FTTH Conference 2025 HFCL Limited, a global pioneer in next-generation telecommunications solutions, has unveiled its innovative Eka™ Optical Fiber at the FTTH Conference 2025. Designed in collaboration with European telecom companies, this groundbreaking fiber aims to bridge the connectivity gaps within rural and urban landscapes of...

Continue Reading
CAI Software Expands Its Manufacturing Throne with PlanetTogether

Updated Category News Views 7

CAI Software's Ambitious Move Who would've guessed, folks? Just another day in the volatile tech landscape, and we see CAI Software splashing the cash to snag PlanetTogether. This isn't just a move to puff up their chest; it's a strategic addition, placing some real weight behind their manufacturing software game. New Horizons with Advanced Planning and Scheduling...

Continue Reading
Artera Expands Its Prostate Test Availability with New License

Updated Category News Views 62

Artera Gains California Lab License to Offer Prostate Test Artera, a leader in artificial intelligence (AI) for cancer diagnostics, recently announced the attainment of its official laboratory license from the California Department of Public Health (CDPH). This important step opens the door for Artera to provide its revolutionary ArteraAI Prostate Test across one of the...

Continue Reading
Bicara Therapeutics Achieves Breakthrough Therapy Milestone for Cancer Treatment

Updated Category News Views 121

Bicara Therapeutics Updates on Financial Results and Business Strategy Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, reports its financial outcomes for the third quarter of 2025 alongside strategic business insights. One of the most noteworthy achievements this quarter is the FDA granting Breakthrough Therapy Designation for...

Continue Reading
ScanTech AI Takes Significant Step with Quarterly Filing Update

Updated Category News Views 179

ScanTech AI's Quarterly Report Filing Details ScanTech AI Systems Inc. is pleased to announce that it has successfully filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC). This filing is a vital step for the company as it aligns with Nasdaq Listing Rule 5250(c)(1), resolving a previous noncompliance issue stemming from a delayed...

Continue Reading